2022
DOI: 10.1186/s12890-022-01922-2
|View full text |Cite
|
Sign up to set email alerts
|

A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies

Abstract: Background The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapies globally. Methods We conducted systematic reviews of ILD disease cost studies and cost-effectiveness analyses (CEAs) using MEDLINE, Embase, and Web of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(3 citation statements)
references
References 57 publications
0
3
0
Order By: Relevance
“…Direct and indirect costs of ILD, including typical IP, were found to be high globally [16]. Timely diagnosis and effective treatment to prevent relapses can limit the mortality and morbidity of the disease.…”
Section: Ethical and Clinical Implications Of The Hypothesismentioning
confidence: 99%
“…Direct and indirect costs of ILD, including typical IP, were found to be high globally [16]. Timely diagnosis and effective treatment to prevent relapses can limit the mortality and morbidity of the disease.…”
Section: Ethical and Clinical Implications Of The Hypothesismentioning
confidence: 99%
“…tobacco smoking) and manifest in older adults as accelerated lung aging [3]. As such, both diseases are associated with significant morbidity, mortality, and a high economic burden to our society [4,5]. Therefore, there is an urgent need for disease prevention and improved treatments.…”
Section: Introductionmentioning
confidence: 99%
“…In 2019, chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions, were the third leading cause of death globally, resulting in 4.0 million deaths and affecting 454.6 million individuals [ 1 , 2 ]. These diseases also impose a substantial burden on healthcare systems owing to hospitalisations, emergency department visits, and long-term care expenses [ 3 6 ]. Furthermore, respiratory infections, including upper and lower respiratory tract infections, contribute to a substantial global burden, with billions of cases and millions of deaths reported annually [ 7 , 8 ].…”
Section: Introductionmentioning
confidence: 99%